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1. Introduction 
Gastric inhibitory polypeptide (GIP) is one of a 
group of polypeptides with distant structural relation- 
ships to the glucagon-secretin family [l-3]. It has 
several effects but two major physiological activities 
have been recognized [4]. One is inhibition of gastric 
acid secretion (enterogastrone ffect), explaining the 
present name and the bioassay followed in the initial 
purification [.5] of the peptide. The other is stimula- 
tion of insulin release when administered in associa- 
tion with hyperglycemia (insulinotropic effect). 
A 43-residue amino acid sequence for the polypep- 
tide was reported in 1971 [ 11. Based on this structure, 
synthetic replicates have been prepared to study the 
biological activity further. The same scheme has been 
followed with other gastrointestinal hormones and has 
usually produced a biologically fully active synthetic 
analogue. A recent example of this verification of a 
new hormone structure [6] is the finding that the 
synthetic form [7] of the mammalian gastrin-releas- 
ing peptide is active. However, in the case of GIP, 
comparisons between natural and synthetic material 
have not unequivocally confirmed the structure [4]. 
Synthetic products appear to contain only part of the 
bioactivity and immunoreactivity [8]. In addition, GIP 
preparations may contain minor components [4]. For 
these reasons, it was decided to re-investigate the pri- 
mary structure of natural GIP preparations. 
The results of a new sequence determination of 
GlP are now reported. It is shown that the previously 
suggested structure apparently is too long by a gluta- 
mine residue after position 29. The structure of the 
main component in GIP preparations described lacks 
this residue and is 42 residues long. It is in agreement 
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with the total composition of native GIP, with results 
of repeated sequence degradations and with the prop- 
erties of smaller fragments that have also been ana- 
lyzed. 
In addition, the present determination confirms 
that the GIP preparation is heterogeneous, and shows 
that the major secondary component appears to be 
identical to the most abundant component except 
that it lacks the first two residues of the latter. The 
second peptide is therefore suggested to be composed 
of residues 3-42 of the major component in the GIP 
preparation. Enzymatic processing as an explanation 
for the origin of the second peptide is discussed. 
2. Materials and methods 
2.1 .GIP 
The active material was extracted from the first part 
of pig upper intestine and purified as in [ 1,4,5]. The 
biological activity was followed by measuring the acid 
inhibitory effects [4]. Analysis by high-performance 
liquid chromatography (HPLC) was done in a Waters 
instrument on a p-Bondapak Crs column using 28% 
acetonitrile, 0.1% phosphoric acid, 71.9% water as 
eluant, and detection at 215 nm. 
2.2. Structural analysis 
GIP (-100 nmol) was cleaved with CNBr (0.1 g) in 
70% formic acid (0.4 ml) at room temperature for 
24 h. A similar sample was cleaved at the two trypto- 
phan residues in 30% acetic acid/S M urea with 
N-chlorosuccinimide (720 pg, added twice with in- 
cubation for 1 h at room temperature after each 
addition). Excess reagent was removed by N-acetyl- 
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methionine (3.5 mg). This scheme follows [9] except 
for a larger excess of N-chlorosuccinimide (50-fold 
over tryptophan). Peptides obtained were purified by 
HPLC in a Waters instrument with a B-Bondapak Cur 
column as above, but with a linear gradient of ethanol 
in an ammonium acetate-acetic acid system. This 
was composed of 5 mM ammonium acetate, 0.1% 
acetic acid, 1% ethanol (solvent A), while the gradient 
mixing solvent B had 89.91% ethanol, 10% solvent A 
and 0.09% acetic acid. Cleavage of G!P (-40 nmol) 
with trypsin (1: 10, w/w) was performed in 0.1 M 
ammonium bicarbonate (0.2 ml) at 37°C for 4 h. 
Amino acids were analyzed with a Beckman 121 M 
analyzer. Samples were hydrolyzed in evacuated tubes 
for 22 h at 1 lO’,C with 6 M HCl/OS% phenol, or for 
tryptophan determination, with 4 M methane sulfonic 
acid/0.2% 3~2-am~oethyl)indote (Pierce). The dansyl- 
Edman method was used for manual sequence analy- 
sis with identi~cation of dansyl-amino acids by thin- 
layer chromatography (TLC) on polyamide layers in 
4 solvent systems [IO]. Liquid-phase sequencer degra- 
dations in a Beckman 890C sequencer were performed 
with a 0.1 M quadrol peptide program in the presence 
of pretreated polybrene, and with identification of 
phenyl~iohydantoin derivatives by HPLC (a Hewlett- 
Packard 1084B instrument) and by TLC, as in [ 1 I]. 
3. Results 
Direct liquid-phase sequencer analysis of the intact 
peptide revealed most of the structure up to residue 
41, as given in fig. 1. This analysis showed that the 
structure in [I] was largely correct, but also suggested 
that there should be 1 instead of 2 glutamine residues 
at positions 29-30. For confirmation, GIP was cleaved 
with CNBr. The peptide mixture obtained was sub- 
mitted to liquid-phase sequencer degradation, without 
separation in order not to miss any fragments. Two 
major sequences, as expected from the presence of 
one methionine in the native peptide, were followed 
for 21 steps (CNI and CN2, fig.l), in agreement with 
the first degradation. 
Manual dansyi-~drn~ analyses were s~nlilarly per- 
formed on a tryptic digest of GIP. Several residues 
were detected in each cycle and could be ascribed to 
the expected fragments Tl --TS (fig.1). Residues 
19-25 were not recovered, probably due to cycliza- 
tion of the N-terminal glutalnine, as noticed before in 
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Fig. 1. Amino acid sequence analysis of GIP, and the structure 
deduced for the major component . Analysis of GIP (- 120 
nmol) and its two CNBr fragments CNI + CN2 (-100 nmol 
in mixture) by liquid-phase sequencer degradations are 
shown by --_x for residues identified by HPLC (values give 
recoveries in nmof of stable thiohydantoinderivatives), and by 
-+for residues also identified by TLC. Repetitive yields in 
the degradations: GIP 94% (Ala 2 + 13), CNl 91% (Tyr 1 
--> 10) and CN2 92% (he 17 -->Leu 27). Analysis of tryptic 
peytides (Tl --T6 in mixture) by manual dansy]-I~dnl~ degra- 
dations are shown by --7r and recovery of the dansylamino 
acid also without hydrolysis, proving the C-terminal position 
is a peptide by Z+ Peptide Wl and W2 are derived from 
~~hiorosu~~inimide cl avages at tryptophan residues, 
tryptic digests [ 111. Instead, the region 26.--30 was 
recovered (T3, fig. 1), due to a chymotryptic-like cleav- 
age, which is also common [ 121. After a few cycles of 
degradation of the mixture, only peptides T3 and T6 
(fig. 1) remained in strong yield (dipeptides T2 and T4 
had ended; Tl and T5 gave low sequence yields due 
to size and tryptophan, respectively). The dansyl re- 
sultsconfirmed the sequencer analyses, the C-terminal 
region (peptide T6), and the C-terminal glutamine 
(fig. I). 
The structure was further confirmed by cleavage 
of GIP with ~~hlorosu~~inimide at tryptophan resi- 
dues and separation of the fragments by HPLC, as 
shown in frg.2. The total composition of fragment W2 
(fig.l), corresponding to peak 1 in fig.%, is shown in 
table 1, and confirms the presence of only 1 gluta- 
mine residue at position 29-30. The entire sequence 
determination is further supported by the total com- 
position of the whole native GIP (also shown in ta- 
ble 1). Consequently, based on these analyses, the 
primary structure of GIP is deduced to be as given in 
figI. 
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Fig.2. Separation of GIP fragments obtained by cleavage with N-chlorosuccinimide at tryptophan residues, HPLC on ti-Bondapak 
C,, with a gradient (as indicated) of solvent B (89.91% ethanol, 10% solvent A and 0.09% acetic acid) in solvent A (5mM ammo- 
nium acetate+ 0.1% acetic acid, 1% ethanol). Flow rate 2 ml/min. The two large peaks &ted just after the start of the gradient are 
due to acetic acid and reagents from the cleavage. The numbered peaks 1,2 and 3 correspond to W2, WI and Wi A, respectively, in 
fig.1 and table 2. 
3.2. Structure of a second component in GIP prepara- 
tions. 
The sequencer degradations of the intact fragment 
and of the CNBr peptide mixture revealed a contami- 
nating sequence in low yield. This sequence was, in all 
positions that could be controlled (i.e., 35 of the first 
38 residues), identical to the rnqjor GE’ sequence 
except for starting at position 3 in the major structure. 
The uncorrected recoveries, shown in table 2, from the 
chromatograph values vary a little due to different 
backgrounds and chromatograph sensitivities, but 
average -2O-25% (table 2). The results therefore sug 
gest that the second component in GIP preparations 
is present in a yield of -20% relative to the major 
component, and that it is a fragment composed of res- 
idues 3-42. No evidence was obtained for any car- 
responding heterogeneity in the C-terminal region, but 
the N-terminal fragment Wl (fig.1) from the trypto- 
phan cleavage was also recovered in two forms (cor- 
responding to peaks 2 and 3 in fig.2). These two forms 
need not be equivalent to pure fragments of the two 
N-terminal components in GIP preparations, but could 
also contain secondary differences due to the pretreat- 
ments (e.g., oxidations or desamidations), but their 
total com~sitions were indistin~i~able, except for 
the first 2 residues in GIP, tyrosine and alanine, which 
show lower values in the minor peak (table 1). The 
presence of a main GIP contaminant in -20% yield, 
compatible with the sequencer results, is confirmed 
by direct fractionation of the GIP preparation on 
HPLC (fig.3). 
4. Discussion 
4.1. structtlre o_fGlP 
The amino acid sequence of GIP was determined 
by a combination of 4 different investigations, analy- 
sis of the intact peptide, analyses of 2 sets of frag- 
ments produced by chemical cleavages, and analysis 
of the tryptic peptides. Although the presence of a 
2-residue shifted contaminant and of ~ternating lysine 
and glycine residues in the criticat region (around posi- 
tion 30) complicated interpretations, the results sug- 
gest that the major component in GIP preparations is 
a 42-residue peptide. All data from sequence degrada- 
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Table 1 
Total compositions of the GIP preparation investigated, and 
of the 2 large peptides after cleavage at tryptophan residues 
with N-chlorosuccinimide 
-- 
Peptide 
composition 
GiP Wla w2a 
- 
Asx 5.6 (6) 4.1 (4) I .o (I) 
Thr 1.9 (2) 0.9 (1) - -- 
Ser 3.2 (3) 1.9 (2) 0.9 (1) 
Glx 5.2 (5) 3.0 (3) 1.1 (1) 
GlY 2.3 (2) 1.2 (1) 1.1 (I) 
Ala 3.1 (3) 1.9 (2) 1.0 (1) 
Val 1.0 (1) 1.0 (1) -- - 
Met 1.2 (1) 0.7 (1) - - 
lie 3.5 (4) 2.7 (3) - 
Leu 2.3 (2) 1.8 (2) 
Tyr 2.2 (2) 1.6 (2) - - 
Phe 2.1 (2) 1.7 (2) - - 
TIP 1.6 (2) (1) (1) 
LYS 4.6 (5) 1.2 (1) 2.7 (3) 
His 1.1 (1) - - 
Arg 1.2 (1) 1.0(l) - - 
Sum 42 25 11 
a Composition of Wl A identical within one decimal digit for 
all residues except Ala (1.7), Tyr (1.3) and Meo (0.4) 
Values shown are molar ratios (values <0.2 omitted) without 
corrections for impurities or hydrolytic destructions, and 
with numbers from the sequence analyses within parentheses. 
Hydrolysis for 22 h with 6 M HCl except for tryptophan in 
GIP which was quantitated after hydrolysis with 4 M methane 
sulfonic acid. Tryptophan destroyed in Wl and W2, as well 
as methionine in Wl , where it was partly recovered as the sul- 
fone. Positions of peptides Wl and W2 are given in fig.1, pep- 
tide Wl A is a variant of Wl, and purification of all 3 peptides 
are shown in fig.2 
tions and from total compositions of the intact prep- 
aration and its proteolytic fragments support the 
structure deduced. This sequence is one internal gluta- 
mine residue shorter than suggested in ]I]. Sign~~c~t- 
ly, it should be noted, however, that the corresponding 
region was previously recovered in low yield and was 
very difficult to analyze [ 11. Furthermore, total com- 
positions reported in ] 131 also agree with this anaiysis 
(table 1) as well as or better than with the previous, 
longer structure. All results therefore suggest hat the 
major peptide in GIP preparations has the structure 
shown in tig.1. 
4.2. Heterogeneity of GIP preparations 
Results from both the fractionation (fig.3) and the 
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sequence analysis (table 2) of the GIP preparation in- 
vestigated show that the material is heterogeneous, 
containing a second component, corresponding to 
-20% of the major component. A hetereogeneity 
Table 2 
Sequence analysis of second component in GIP preparations 
- _-- -__ 
Cycle Residue 
identified 
- 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
Average 
recovery 
GlU 
GlY 
Thr 
Phe 
lle 
Ser 
Asp 
Tyr 
Ser 
Ile 
Ala 
Met 
ASP 
LYS 
Ile 
(Arg) 
Gln 
Gin 
Asp 
Phe 
Val 
Asn 
Trp 
LeU 
Leu 
Ala 
Ghl 
LYS 
GlY 
LYS 
LYS 
(Ser) 
Asi’ 
Trp 
LYS 
(His) 
Asn 
Ile 
~__ -____ 
%, of main component from 
degradation of 
-__-I____ 
GIP prep. CNBr peptide mix. 
___~_-~-II__. 
25 20 
15 25 
15 25 
25 20 
30 30 
10 - 
20 - 
25 15 
20 - 
35 25 
10 20 
30 - 
20 Average 
25 recovery: 23% 
20 
- 
25 
10 
20 
35 
20 
15 
30 
10 
15 
35 
15 
25 
25 
30 
25 
- 
20 
20 
25 
- 
20 
10 
21% 
- 
The amount of each residue is given as % recovered in relation 
to the recovery of the same residue 2 cycles later in the main 
component. Degradations in a liquid-phase sequencer and 
quantitation in a high-performance liquid chromatograph 
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Fig.3. Separation of the GIP preparation by HPLC on 
r-Bondapak C,, in 0.1% phosphoric acid, 28% acetonitrile, 
71.9% water. Flow rate: 1.5 ml/min. A main component and 
a major second component are clearly seen apart from a minor 
third fraction. 
had been reported, but the minor component was then 
reported to be present in lower yield, 5% [4] than the 
present second component. It appears possible that 
the degree of heterogeneity can vary between prepa- 
rations, or that the third component in fig.3 was that 
previously detected. The structure of the second pep- 
tide is identical to residues 3-42 of the main form. 
The extensive similarity between the two components 
explains why they do not separate easily during the 
purification steps performed, and why a contamina- 
tion of up to 20% or more, is still not visible in the 
total composition, as evidenced by the agreement 
between hydrolytic values (table 1; [ 131) and the 
sequence of the main component (fig.1). An N-termi- 
nal heterogeneity with peptide chains that have not 
been separately purified, has also been found in prep- 
arations of bovine somatotropin [ 14-161. 
The presence of a shorter but otherwise apparently 
identical second component raises questions on its 
origin and bioactivity. Regarding the origin, the struc- 
ture of the deviating part, Tyr-Ala, is not at all remi- 
niscent of the longer and C-terminally dibasic struc- 
tures usually removed on regular processings of pro- 
hormone forms (cf, table 2 in [ 171). Consequently, 
it does not appear likely that the two peptides in the 
GIP preparations represent usual prohormone-hor- 
mone forms. Instead, one possibility is that they are 
derived from different partly duplicated genes or dif- 
ferent regions of a larger gene, if they are not just al- 
lelic variants. Deletion mutants have been detected in 
human somatotropin [ 181. A genetic multiplicity for 
GIP would be compatible with the already large group 
of peptides related in that way [2,3] and with the 
multiple genetic origin of structures for hormones 
like melanotropin [ 191. However, a different and per- 
haps more likely possibility is that the two forms in 
the GIP preparation are derived from secondary pro- 
cessings (or even degradations) through susceptibility 
to attack by aminopeptidase, elastase, dipeptidyl 
aminopeptidase or related enzymes in the intestine. It 
is even possible that the third component visible in 
fig.3 is one additional, processed form. Indeed, in view 
of the biological origin of GIP and other intestinal 
hormones, such an explanation for the origin of the 
second component in GIP preparations would appear 
less surprising than the facts that heterogeneities are 
not more frequently found among gastrointestinal 
peptides. A dipeptidyl peptidase has recently also been 
implied in another peptide conversion (of promelittin 
in the bee, [20]). 
Regarding the bioactivity of GIP preparations, the 
discovery of two related peptides will necessitate fur- 
ther physiological studies. The main GIP component 
is already known to be active [4], but if this relates to 
both the main activities (enterogastrone ffect and in- 
sulinotropic activity) and all other activities is un- 
known (cf. [4]). The possible activity of the second 
component is unknown but a biological activity cannot 
be excluded in view of the significant but reduced ac- 
tivity even of internally elongated synthetic analogues 
[8]. If the shorter form has altered bioactivities, wider 
structure-function relationships can be deduced from 
further studies of its properties. 
Independent of future results on the origin and 
activity of both GIP components, the present results 
indicate one explanation of previous failures with syn- 
thetic analogues, show a new structure for GIP, and 
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establish the nature of a minor peptide constituent in 
the preparation. 
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